Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.09 Analyst target: $3.90 Upside: 86.60%
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.